Latest news from Iconovo

Iconovo to present positive data from a feasibility study on Nanofitins in ICOone

Iconovo AB and Affilogic today announce that Iconovo will present positive results from a feasibility study with a Nanofitin based biologic drug against…

Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea

Iconovo announces that the company will receive a grant of SEK 680,000 from Innowwide. The grant will be used to carry out a market study to introduce…

Biostock: Iconovo inleder 2024 med order från ledande läkemedelsbolag

Iconovo har erhållit en order från ett av världens tio största läkemedelsbolag. Dessutom stärker bolaget sin CDMO-affärsmodell genom att ingå ytterligare…

Meet us



April 24-25, 2024


RDD, Respiratory Drug Delivery 2024

May 5-9, 2024

Tucson, Arizona

Bio International Convention

June 3-6, 2024

San Diego

NLS Days 

September 17-19, 2024



October 8-10, 2024



Redeye Life Science Days 

November 28, Stockholm

We are a specialized CDMO that develops inhalation products in our patented, innovative inhalers, supporting customers in bringing their inhaled treatments to market.

Learn more


Four differentiated technical platforms

We develop inhaled medicines from your drug substance as your complete inhalation partner. We take you all the way through your pharmaceutical product development, from idea to finalized inhalation product. Our strength is the integrated development of inhaler and dry powder formulation. Four differentiated technical inhaler platforms can be optimized with your unique dry powder formulation, and we also assist with manufacturing of clinical trial material in early clinical trials and technical documentation for registrations.

Learn more


Engineering and pharmaceutical expertise

Iconovo has an integrated development process, with all competences and facilities inhouse. With a unique combination of engineering and pharmaceutical expertise, our capabilities include devices, formulation, pharmaceutical analysis, and advisory services.

Learn more

Stay up to date with Iconovo’s news and press releases